Based on previous findings suggesting a role for IL-1β in modulating chemotherapeutic response to oxaliplatin in colon cancer cell line HCT 116 (16), we assessed if the presence of IL-1β would interfere with the cellular response to 5-FU, a standard chemotherapeutic agent used in the treatment of CRC. Here, IL1B is linked to malignant colon neoplasm.